Plasma　with　low　temperature　generated　at　atmospheric　pressure　is　known　as　cold　atmospheric　plasma　(CAP).　Owing　to　its　unique　characteristics　and　biological　effects　of　inducing　tumor　cell　death　without　endangering　the　surrounding　healthy　tissues,　CAP　is　regarded　as　an　emerging　potent　anticancer　strategy　and　has　been　extensively　investigated　in　preclinical　research.　In　this　review,　we　define　the　reactive　species　that　play　a　major　role　in　CAP　as　a　novel　＇drug＇　(termed　as　plasma　drug)　used　in　cancer　therapy.　Various　methods　of　plasma　drug　use　in　tumor　treatment　were　summarized,　mainly　including　plasma　drug　direct　delivery,　carriers　for　plasma　drug,　plasma　drug　synergistic　immunotherapy,　plasma　drug　in　combination　with　nanoparticle　therapy,　plasma　drug　delivery　with　other　anti-tumor　drugs,　and　biomedical　devices　assisted　plasma　drug　delivery.　Furthermore,　we　provide　prospective　on　the　future　development　of　plasma　drug　for　cancer　therapy.　Plasma　drug　has　the　potential　to　evolve　into　a　novel　class　of　cancer　therapy　with　continued　technology　improvements　and　multidisciplinary　research　efforts,　providing　patients　with　effective　and　individualized　treatment　alternatives.　©　2025　Elsevier　B.V.